6 analysts have shared their evaluations of ADMA Biologics (NASDAQ:ADMA) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.58, along with a high estimate of $14.00 and a low estimate of $7.50. This upward trend is evident, with the current average reflecting a 23.31% increase from the previous average price target of $8.58.
Investigating Analyst Ratings: An Elaborate Study
The...
Login or create a forever free account to read this news
Sign up/Log in